Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

News | May 30, 2014
May 30, 2014 — Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere...
News | April 29, 2014
April 29, 2014 — Armetheon Inc. announced it has reached agreement with the U.S. Food and Drug Administration (FDA) on...
Feature | April 10, 2014
April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations...
Feature | April 07, 2014
April 7, 2014 — In a comparison of two blood-thinning medications, heparin was associated with significantly fewer...
News | March 25, 2014
March 25, 2014 — Patient enrollment has been completed four months ahead of plan in the Phase III clinical trial EUCLID...
Medtronic Endeavor Stents Drug-eluting Antiplatelet Therapy Clinical Study
News | March 18, 2014
March 18, 2014 — Patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from...
News | March 12, 2014
March 12, 2014 — Janssen Research and Development LLC (Janssen) announced the U.S. Food and Drug Administration (FDA)...
News | February 27, 2014
February 27, 2014 — Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their...
News | February 03, 2014
February 3, 2014 — A large-scale analysis assessing the real-world risk of venous thromboembolism (VTE) in chemotherapy...
News | January 22, 2014
January 22, 2014 — The U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs Advisory Committee...
News | January 22, 2014
January 22, 2014 — The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee...
News | January 14, 2014
January 14, 2014 — Daiichi Sankyo Company Ltd. announced results from the Phase 3 ENGAGE AF-TIMI 48 study [1]. The...
acc pharmaceuticals renal denervation heart valve repair antiplatelet therapy
Feature | December 24, 2013
December 24, 2013 — Clinical trials for a promising new class of cholesterol-lowering medications, a long-awaited...
News | December 17, 2013
December 17, 2013 — CSL Behring announced that Kcentra (Prothrombin Complex Concentrate [Human]) has received U.S. Food...
clinical trial study antiplatelet thomas jefferson cath function monitors
News | December 12, 2013
December 12, 2013 — Thomas Jefferson University researchers discovered that the formation of blood clots follows a...